BUCHANG PHARMA(603858)2025-01-20 10:25Financial Performance Expectations - The company expects a net loss attributable to shareholders of approximately -808 million to -428 million yuan for the year 2024, indicating a significant decline compared to a net profit of 318.97 million yuan in the same period last year [4][6]. - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between -708 million and -368 million yuan for 2024 [4][6]. - The previous year's earnings per share was reported at 0.2884 yuan [8]. Reasons for Expected Loss - The primary reason for the expected loss is goodwill impairment related to subsidiaries, with an anticipated impairment provision of approximately 700 million to 1 billion yuan [9]. - The company has faced reduced sales due to certain products being restricted by medical insurance or included in key monitoring directories in some provinces, leading to a decrease in revenue and a change in product revenue structure [9]. Goodwill Impairment and Forecast Accuracy - The goodwill impairment testing is ongoing, and the final amount will be determined by a qualified evaluation and auditing institution [9]. - The company has not identified any significant uncertainties that could affect the accuracy of this earnings forecast [10]. Data Disclosure and Final Reporting - The data provided is preliminary and subject to change, with the final audited financial data to be disclosed in the official annual report for 2024 [11].